CEO Comments

CEO Comment Annual Report 2022

27 March, 2023

Closer to a commercial break-through In 2022, Nanologica has taken several steps forward – we launched our product in preparative chromatography, took our first orders for this product and listed the company on Nasdaq Main Market. We did not reach the goal of delivering products, but have gradually come closer. We are committed to achieving a commercial breakthrough in 2023. 2022 has been characterized by an unstable situation in the world and great uncertainties in

CEO Comment Q4 2022

13 February, 2023

FOCUS ON PRODUCTION A continued focus on production has characterized both the fourth quarter and the beginning of the new year. At the same time, our view of the market needs for additional suppliers of high-quality silica for preparative chromatography was strengthened. During the fourth quarter, our main focus has continued to be on production. We manufacture silica on a large scale and as we previously have described, we are satisfied with our product, but

CEO Comment Q3 2023

11 November, 2022

WELL-POSITIONED FOR THE NEXT PHASE Our focus during the third quarter has mainly been on production and financing. We are now producing on a large scale in our production line, while having secured financing to intensify our investments in preparative chromatography and deliver on the order book we are starting to build. During the third quarter, we received several orders for the evaluation of NLAB Saga®, our silica for preparative chromatography, including one order from

CEO Comment in Connection with the Preferential Rights Issue 2022

20 September, 2022

In 2022, Nanologica has taken important steps forward in the chromatography business area. We have scaled up the production of our commercial silica for preparative chromatography, NLAB Saga®, to tonal scale, and we have sold the first products in preparative chromatography, as well as taken orders for NLAB Saga® for production-scale evaluation from one of the world’s largest insulin manufacturers. The fact that we now have products from our large-scale production means that we can

CEO Comment Q2 2022

19 August, 2022

ORDER FROM INSULIN MANUFACTURERS LAYS FOUNDATION FOR CHARGING FORWARD During the quarter, we launched our product line NLAB Saga® for preparative chromatography, after finalizing large volumes of the first products at the large-scale production facility. NLAB Saga® has initially been very well received by customers, which was shown by an order from one of the world’s largest insulin manufacturers in August, for evaluation of the product at production scale. If the products meet the customer’s

CEO Comment Q1 2022

9 May, 2022

A NEW CHAPTER BEGINS On March 29, 2022, a new chapter in Nanologica’s history began – as listed on a regulated market. By listing the share on Nasdaq Stockholm Main Market, we get an increased exposure and a better opportunity to attract institutional and international owners. At the same time, we are now launching our products for preparative chromatography. The big event of the quarter was the change of lists to Nasdaq Stockholm Main Market,

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.

Read more:

Categories

Archive per year